Moms on IBD drug help science understand breastfeeding safety
NCT ID NCT06346288
Summary
This study aimed to measure how much of the IBD medication risankizumab passes into breast milk. It involved 10 breastfeeding women with inflammatory bowel disease who were already receiving the drug as part of their regular treatment. Researchers collected breast milk samples over about 7 months to understand the drug's concentration, helping to inform future safety guidance for nursing mothers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shaare Zedek Medical Center /ID# 262738
Jerusalem, Jerusalem, 91031, Israel
-
UTHealth Women's Research Program - Memorial City /ID# 263939
Houston, Texas, 77024, United States
-
University of North Carolina at Chapel Hill /ID# 263316
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.